ESC working group cellular biology of the heart: Position paper: Improving the preclinical assessment of novel cardioprotective therapies

Sandrine Lecour, Hans E. Bøtker, Gianluigi Condorelli, Sean M. Davidson, David Garcia-Dorado, Felix B. Engel, Peter Ferdinandy, Gerd Heusch, Rosalinda Madonna, Michel Ovize, Marisol Ruiz-Meana, Rainer Schulz, Joost P.G. Sluijter, Linda W. Van Laake, Derek M. Yellon, Derek J. Hausenloy

Research output: Contribution to journalReview articleResearchpeer-review

101 Citations (Scopus)

Abstract

© The Author 2014. Ischaemic heart disease (IHD) remains the leading cause of death and disability worldwide. As a result, novel therapies are still needed to protect the heart fromthe detrimental effects of acute ischaemia-reperfusion injury, in order to improve clinical outcomes in IHD patients. In this regard, although a large number of novel cardioprotective therapies discovered in the research laboratory have been investigated in the clinical setting, only a few of these have been demonstrated to improve clinical outcomes. One potential reason for this lack of success may have been the failure to thoroughly assess the cardioprotective efficacy of these novel therapies in suitably designed preclinical experimental animal models. Therefore, the aim of this Position Paper by the European Society of CardiologyWorkingGroup Cellular Biology of the Heart is to provide recommendations for improving the preclinical assessment of novel cardioprotective therapies discovered in the research laboratory, with the aim of increasing the likelihood of success in translating these new treatments into improved clinical outcomes.
Original languageEnglish
Pages (from-to)399-411
JournalCardiovascular Research
Volume104
Issue number3
DOIs
Publication statusPublished - 1 Jan 2014

Keywords

  • Animal models
  • Cardioprotection
  • Ischaemia
  • Myocardial infarction
  • Reperfusion

Fingerprint Dive into the research topics of 'ESC working group cellular biology of the heart: Position paper: Improving the preclinical assessment of novel cardioprotective therapies'. Together they form a unique fingerprint.

Cite this